Endologix Inc. Reports 32% Revenue Growth for the First Quarter 2012

April 27, 2012 |

1 min read

IRVINE, Calif., April 26, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2012.

Earnings

MORE ON THIS TOPIC

Sign of divorce. Broken paper heart on blue background, top view, copy space

Business

Novo Breaks $598M Heartseed Pact Amid ‘Decisive Restructuring’ by New CEO

October 1, 2025

·

2 min read

·

Tristan Manalac

Tablets. Medicinal capsules on a white background. pharmacies in the country. medicines in the state. Lots of capsules for treatment. Pharmacy network of the country.

Opinion

The Urgent Need To Redefine the Future of UK Biotech

October 1, 2025

·

6 min read

·

Kerstin Papenfuss

Company downsizing, staff reduction and layoffs. Employee dismissal, firing and unemployment. Business concept.

Layoffs

Sutro Makes Deeper Cuts To Extend Runway Into 2027, Reach Key Data Readout

September 30, 2025

·

1 min read

·

Dan Samorodnitsky

Rheumatoid arthritis (RA) commonly causes inflammation in the hands, leading to pain, swelling, and stiffness in the joints, particularly the small joints of the fingers and wrists. This inflammation results from the immune system attacking the body's own joint tissues, causing the synovium (lining of the joint) to become inflamed and release chemicals that damage nearby tissues.

Series A

Novo-Backed Crystalys Debuts With $205M to Tackle Gout

September 30, 2025

·

2 min read

·

Tristan Manalac